Polymorphic forms of deoxycytidine, compositions comprising the same and uses
Polymorphic forms of deoxycytidine and methods for preparing the same are provided herein. Also provided are compositions comprising polymorphic forms of deoxycytidine and at least one residual solvent, as well as methods of treating mitochondrial diseases using said compositions.
1. A composition comprising Form B deoxycytidine and at least one residual solvent, wherein
Form B deoxycytidine is characterized by a powder X-ray diffraction (XRPD) pattern comprising peaks at 13.7, 17.2, 18.0, 19.2 and 22.8 degrees 2θ (±0.2 degrees 2θ), and
the at least one residual solvent is selected from the group consisting of methanol, toluene, methylene chloride, ethanol, tert-butylmethyl ether, acetone, ethyl acetate, and n-heptane, and the concentration of the at least one residual solvent is less than about 10% of the ICH concentration limit for each residual solvent;
wherein the composition is stable for at least 3 months at 25±2° C. and 60±5% relative humidity.
2. The composition of claim 1 , wherein the Form B deoxycytidine further comprises one or more of the following XRPD peaks: 11.5, 11.8, 20.2, 21.1, 21.4 and 21.8 degrees 2θ (±0.2 degrees 2θ).
3. The composition of claim 1 , comprising less than about 100 ppm ethyl acetate, less than about 100 ppm n-heptane and less than about 200 ppm ethanol.
4. The composition of claim 1 , comprising less than about 70 ppm ethyl acetate, less than about 50 ppm n-heptane and less than about 200 ppm ethanol.
5. The composition of claim 1 , wherein composition comprises at least one of the following: (a) from 1 ppm to about 300 ppm methanol, (b) from 1 ppm to about 89 ppm toluene, (c) from 1 ppm to about 60 ppm methylene chloride (d) from 1 ppm to about 500 ppm ethanol, (e) from 1 ppm to about 500 ppm TBME, (f) from 1 ppm to about 500 ppm acetone, (g) from 1 ppm to about 500 ppm ethyl acetate, and (h) from 1 ppm to about 500 ppm n-heptane.
6. The composition of claim 1 , wherein 1,2-dichloroethane is undetectable.
7. The composition of claim 1 , further comprising at least one pharmaceutically acceptable carrier.
8. The composition of claim 1 , further comprising deoxythymidine.
9. A fixed-dose pharmaceutical composition comprising Form B deoxycytidine, deoxythymidine, at least one residual solvent and at least one pharmaceutically acceptable carrier, wherein:
a. the at least one residual solvent is selected from the group consisting of methanol, toluene, methylene chloride, ethanol, tert-butylmethyl ether, acetone, ethyl acetate, and n-heptane, and the concentration of the at least one residual solvent is less than about 10% of the ICH concentration limit for each residual solvent;
b. the composition is in the form of a powder;
c. the weight ratio of deoxycytidine and deoxythymidine is 50:50; and
d. Form B deoxycytidine is characterized by a powder X-ray diffraction (XRPD) pattern comprising peaks at 13.7, 17.2, 18.0, 19.2 and 22.8 degrees 2θ (±0.2 degrees 2θ);
wherein the composition is stable for at least 3 months at 25±2° C. and 60±5% relative humidity.
10. The composition of claim 9 , wherein the at least one pharmaceutically acceptable carrier comprises at least one glidant and at least one lubricant.
11. The composition of claim 10 , wherein the at least one glidant is present in an amount from about 0.1 wt % to about 10 wt %.
12. The composition of claim 11 , wherein the at least one glidant comprises colloidal silicon dioxide.
13. The composition of claim 10 , wherein the at least one lubricant is present in an amount from about 0.1 wt % to about 1 wt %.
14. The composition of claim 13 , wherein the at least one lubricant comprises magnesium stearate.
15. The composition of claim 10 , wherein deoxycytidine is present in an amount from about 40 wt % to about 50 wt %.
16. The composition of claim 10 , wherein the powder is packaged in a pouch.
17. A method for preparing substantially pure Form B deoxycytidine comprising:
a. providing crude deoxycytidine comprising a mixture of Form A and Form B polymorphic forms;
b. contacting the crude deoxycytidine with ethanol to provide a first mixture;
c. distilling ethanol from the first mixture to provide a residue;
d. contacting the residue with purified water to provide a second mixture;
e. heating the internal temperature of the second mixture to an internal temperature of at least about 40° C.;
f. adding ethanol, ethyl acetate and heptane to the second mixture to provide a third mixture;
g. cooling the third mixture to provide substantially pure Form B deoxycytidine crystals; and
h. separating the substantially pure Form B crystals from the third mixture.
18. The method of claim 17 , wherein in (f) a first portion of ethanol is added to the second mixture following by a solution comprising a second portion of ethanol, ethyl acetate and n-heptane.
19. The method of claim 17 , wherein the third mixture in (g) is cooled to an internal temperature from about 0° C. to about 10° C.
20. A method for treating TK2 deficiency in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising Form B deoxycytidine and at least one residual solvent selected from the group consisting of methanol, toluene, methylene chloride, ethanol, tert-butylmethyl ether, acetone, ethyl acetate, and n-heptane, wherein the concentration of the at least one residual solvent is less than about 10% of the ICH concentration limit for each residual solvent;
wherein Form B deoxycytidine is characterized by a powder X-ray diffraction (XRPD) pattern comprising peaks at 13.7, 17.2, 18.0, 19.2 and 22.8 degrees 2θ (±0.2 degrees 2θ); and
wherein the composition is stable for at least 3 months at 25±2° C. and 60±5% relative humidity.
21. The method of claim 20 , further comprising treating the subject with a therapeutically effective amount of a second composition comprising deoxythymidine.
22. The method of claim 21 , wherein the ratio of deoxycytidine to deoxythymidine is about 50/50.
23. The method of claim 21 , wherein the second composition is administered to the subject in a daily dose of between about 100 mg/kg/day and about 1,000 mg/kg/day.
24. The method of claim 20 , wherein the composition is administered to the subject in a daily dose of between about 100 mg/kg/day and about 1,000 mg/kg/day.
25. A method for treating TK2 deficiency in a subject in need thereof comprising
(a) dissolving a fixed-dose powder composition in water to provide a solution, wherein the powder composition comprises Form B deoxycytidine, deoxythymidine, at least one residual solvent and at least one pharmaceutically acceptable carrier, wherein
the at least one residual solvent is selected from the group consisting of methanol, toluene, methylene chloride, ethanol, tert-butylmethyl ether, acetone, ethyl acetate, and n-heptane, and the concentration of the at least one residual solvent is less than about 10% of the ICH concentration limit for each residual solvent; and
wherein the ratio of deoxycytidine to deoxythymidine is about 50/50; and
(b) administering the solution to a subject in need thereof;
wherein Form B deoxycytidine is characterized by a powder X-ray diffraction (XRPD) pattern comprising peaks at 13.7, 17.2, 18.0, 19.2 and 22.8 degrees 2θ (±0.2 degrees 2θ);
wherein the composition is stable for at least 3 months at 25±2° C. and 60±5% relative humidity.
26. The method of claim 25 , wherein the composition comprises from about 1,000 mg to about 5,000 mg of each of Form B deoxycytidine and deoxythymidine.
27. The method of claim 26 , wherein the composition comprises about 2,000 mg of each of Form B deoxycytidine and deoxythymidine.